Acquisition and $200M financing drive VT-7208 phase II trials
Processa Pharmaceuticals says a major acquisition plus $200 million financing will support parallel phase II trials of VT-7208, a BTK inhibitor for food allergy, CSU, and relapsing MS, with key readouts expected in 2027–2028.
Story updates
12:18:22 PM UTC
SquawkNews
A major acquisition and $200 million financing enable parallel phase II development of a differentiated BTK inhibitor for food allergy, CSU, and relapsing MS, with initial data expected in 2027—2028. Strong phase I data support once-daily dosing and a favorable safety profile.Based on Processa Phar…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.